Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001420538
Ethics application status
Approved
Date submitted
17/11/2024
Date registered
4/12/2024
Date last updated
16/02/2025
Date data sharing statement initially provided
4/12/2024
Type of registration
Retrospectively registered
Titles & IDs
Public title
Comparison of clinical outcomes of left bundle branch pacing vs right ventricular pacing in patients with normal left ventricular function or mild dysfunction
Query!
Scientific title
A randomized trial of left bundle branch area pacing vs right ventricular pacing in patients with preserved or mildly impaired left ventricular ejection fraction- PACE HF
Query!
Secondary ID [1]
313393
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pacing induced cardiomyopathy
335761
0
Query!
Condition category
Condition code
Cardiovascular
332318
332318
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Left bundle branch area pacing (LBBAP) will be studied. LBBAP involves implanting the pacing lead in the left bundle branch (LBB) or left ventricular septal location. The intervention will be performed in pacing indicated patients randomized to LBBAP arm. In LBBAP, the ventricular lead is implanted deep in the septum to capture LBB or left ventricular septum (LVS). The final location of the lead is determined based on electrocardiographic criteria as below:
Paced RBBB morphology plus at least one of the following:
1. R wave peak time in lead V6 <80 ms in patients with a bundle branch block and <75 ms in patients with narrow complex QRS
2. Transition from non-selective to selective LBB or left ventricular septal capture seen
3. V6-V1 interval <44 ms
The intervention will be performed by cardiac electrophysiologist with >5 years of experience in implanting LBBAP pacemaker. The intervention will be performed only once during the study unless lead failure or infection mandates lead revision/removal. The intervention will be performed at National Capital Private Hospital. The usual duration to perform this LBBAP implant is 60-90 mins. ECGs will be done at each follow up to monitor persistence of LBB/LVS capture.
Query!
Intervention code [1]
329970
0
Treatment: Devices
Query!
Comparator / control treatment
Right ventricular pacing (RVP) will be the comparator arm. RVP is a standard pacing strategy for >6 decades. The pacing lead is implanted into the right ventricular apex or right ventricular septum.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
339897
0
Left ventricular ejection fraction
Query!
Assessment method [1]
339897
0
Echocardiography
Query!
Timepoint [1]
339897
0
Baseline, 6 months and 12 months post-implantation
Query!
Secondary outcome [1]
441853
0
Quality of life
Query!
Assessment method [1]
441853
0
EQ5D5L questionnaire
Query!
Timepoint [1]
441853
0
Baseline and 12 months post-implantation
Query!
Secondary outcome [2]
441838
0
Left ventricular end-systolic volume
Query!
Assessment method [2]
441838
0
Echocardiography
Query!
Timepoint [2]
441838
0
Baseline, 6 months, 12 months post-implantation
Query!
Secondary outcome [3]
441840
0
Left ventricular mass
Query!
Assessment method [3]
441840
0
Echocardiography
Query!
Timepoint [3]
441840
0
Baseline, 12 months post-implantation
Query!
Secondary outcome [4]
441845
0
Pacing burden
Query!
Assessment method [4]
441845
0
Pacemaker interrogation
Query!
Timepoint [4]
441845
0
6 months, 12 months post-implantation
Query!
Secondary outcome [5]
441849
0
Incidence of atrial fibrillation of >30 seconds
Query!
Assessment method [5]
441849
0
From device interrogation
Query!
Timepoint [5]
441849
0
6 months and 12 months post-implantation
Query!
Secondary outcome [6]
441843
0
Heart failure hospitalizations
Query!
Assessment method [6]
441843
0
Clinical records and history
Query!
Timepoint [6]
441843
0
6 months, 12 months post-implantation
Query!
Secondary outcome [7]
441839
0
Left ventricular global longitudinal strain
Query!
Assessment method [7]
441839
0
Echocardiography
Query!
Timepoint [7]
441839
0
Baseline, 6 months, 12 months post-implantation
Query!
Secondary outcome [8]
441842
0
Symptom assessment- New York Heart Association (NYHA) classification
Query!
Assessment method [8]
441842
0
Clinical history by attending physician
Query!
Timepoint [8]
441842
0
Baseline, 12 months post-implantation
Query!
Secondary outcome [9]
441841
0
Right ventricular systolic pressure
Query!
Assessment method [9]
441841
0
Echocardiography
Query!
Timepoint [9]
441841
0
Baseline, 6 months, 12 months post-implantation
Query!
Secondary outcome [10]
441854
0
QRS duration
Query!
Assessment method [10]
441854
0
Electrocardiogram
Query!
Timepoint [10]
441854
0
Baseline, at implant and 12 months post-implantation
Query!
Secondary outcome [11]
442149
0
Left atrial strain
Query!
Assessment method [11]
442149
0
Echocardiography
Query!
Timepoint [11]
442149
0
Baseline and 12 months post implant
Query!
Secondary outcome [12]
441848
0
Device related complications such as injury to valvular tissue/leaflet entrapment leading to regurgitation, cardiac perforation, pericardial effusion, cardiac tamponade necessitating pericardial tapping, vascular injury, wound hematoma/infection, lead dislodgment necessitating lead replacement
Query!
Assessment method [12]
441848
0
Assessment by implanting physician, echocardiography, chest X-ray
Query!
Timepoint [12]
441848
0
From the time of implant to discharge from hospital. Subsequently, evaluation for complications will be conducted only if the patient presents with symptoms that are clinically deemed to be associated with a device-related complication.
Query!
Secondary outcome [13]
441844
0
Lead threshold
Query!
Assessment method [13]
441844
0
Pacemaker interrogation
Query!
Timepoint [13]
441844
0
At implant, 6 months, 12 months post-implantation
Query!
Secondary outcome [14]
441846
0
Loss of left bundle branch capture
Query!
Assessment method [14]
441846
0
Electrocardiography
Query!
Timepoint [14]
441846
0
6 months, 12 months post-implantation
Query!
Secondary outcome [15]
441852
0
Left atrial volume
Query!
Assessment method [15]
441852
0
Echocardiography
Query!
Timepoint [15]
441852
0
Baseline and 12 months post-implantation
Query!
Eligibility
Key inclusion criteria
1. Age: above 18 years
2. AV block or any other bradyarrhythmia with pacing burden of >40%
3. Left ventricular ejection fraction (LVEF) >35%
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. LVEF <35%
2. Patients with biventricular pacing
3. Patients with structural heart disease
4. Patients with alternative pathology which can cause LV dysfunction, such as severe MR, severe AS or AR
5. Patients with atrial fibrillation
6. Patients for ‘pace and ablate’ therapy
7. Patients being considered for epicardial pacing
8. Patients refused to provide consent
9. Limited life expectancy due to comorbidity
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/11/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
11/12/2023
Query!
Date of last data collection
Anticipated
13/12/2024
Query!
Actual
24/12/2024
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
120
Query!
Recruitment in Australia
Recruitment state(s)
ACT
Query!
Funding & Sponsors
Funding source category [1]
317832
0
Other Collaborative groups
Query!
Name [1]
317832
0
Canberra heart rhythm foundation
Query!
Address [1]
317832
0
Query!
Country [1]
317832
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Canberra heart rhythm
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
320166
0
None
Query!
Name [1]
320166
0
Query!
Address [1]
320166
0
Query!
Country [1]
320166
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316518
0
ACT Health Human Research Ethics Committee
Query!
Ethics committee address [1]
316518
0
https://health.act.gov.au/act-health-system/research-data-and-publications/research/research-ethics-and-governance
Query!
Ethics committee country [1]
316518
0
Australia
Query!
Date submitted for ethics approval [1]
316518
0
02/07/2021
Query!
Approval date [1]
316518
0
29/10/2021
Query!
Ethics approval number [1]
316518
0
Query!
Summary
Brief summary
This study aims at evaluating effect of LBBAP on clinical outcomes in comparison to RVP which has been a gold standard for six decades. The study hypothesis is that the LBBAP is more effective for pacing in patients with mild LV dysfunction or normal LV function. The study is aimed at evaluating LBBAP's efficacy in patients with LVEF >35%. Primary outcome measure is effect on LVEF. Secondary outcome measures include incidence of heart failure hospitalization, new onset atrial fibrillation and evaluation of structural changes in heart. The minimum follow up in this trial was 1 year.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
138138
0
Prof Rajeev K Pathak
Query!
Address
138138
0
Canberra heart rhythm, Suite 14, 2 Garran place, Garran, ACT
Query!
Country
138138
0
Australia
Query!
Phone
138138
0
+61 02 51122532
Query!
Fax
138138
0
Query!
Email
138138
0
[email protected]
Query!
Contact person for public queries
Name
138139
0
Rajeev K Pathak
Query!
Address
138139
0
Canberra heart rhythm, Suite 14, 2 Garran place, Garran, ACT
Query!
Country
138139
0
Australia
Query!
Phone
138139
0
+61 02 51122532
Query!
Fax
138139
0
Query!
Email
138139
0
[email protected]
Query!
Contact person for scientific queries
Name
138140
0
Rajeev K Pathak
Query!
Address
138140
0
Canberra heart rhythm, Suite 14, 2 Garran place, Garran, ACT
Query!
Country
138140
0
Australia
Query!
Phone
138140
0
+61 02 51122532
Query!
Fax
138140
0
Query!
Email
138140
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF